Leerink Partners Downgrades Quanterix(QTRX.US) to Hold Rating, Cuts Target Price to $8
Leerink Partners Downgrades Quanterix to Market Perform, Lowers Price Target to $8
Quanterix Analyst Ratings
Quanterix (QTRX) Receives a Buy From Leerink Partners
TD Cowen Maintains Quanterix(QTRX.US) With Hold Rating, Cuts Target Price to $7.5
Scotiabank Maintains Quanterix(QTRX.US) With Buy Rating, Cuts Target Price to $18
Quanterix Analyst Ratings
Scotiabank Maintains Sector Outperform on Quanterix, Lowers Price Target to $18
Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Xoma (XOMA)
CCORF Maintains Quanterix(QTRX.US) With Buy Rating, Cuts Target Price to $15
Quanterix Is Maintained at Buy by Canaccord Genuity
Quanterix Analyst Ratings
Buy Rating Affirmed for Quanterix Amid Strong Q4 Performance and Strategic Merger With Akoya Biosciences
TD Cowen Maintains Quanterix(QTRX.US) With Hold Rating, Cuts Target Price to $10
Quanterix: Hold Rating Amid Short-Term Challenges and Long-Term Opportunities
Quanterix Buy Rating Supported by Instrument Sales Recovery, Strategic Growth Opportunities, and Promising Market Potential
CCORF Maintains Quanterix(QTRX.US) With Buy Rating, Maintains Target Price $20
Canaccord Genuity Reaffirms Their Buy Rating on Quanterix (QTRX)
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Quanterix (QTRX) and Walgreens Boots Alliance (WBA)
TD Cowen Reaffirms Their Hold Rating on Quanterix (QTRX)